Reduced bladder capacity in patients receiving intravesical chemoprophylaxis with mitomycin C

After complete resection of superficial bladder carcinoma (Tis-2, G1-3), 75 patients were treated prophylactically with either 20 or 30 mg mitomycin C. Six patients developed a substantial reduction in bladder capacity (less than 200 ml). In 2 patients radical cystectomy of an otherwise tumour-free...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of urology Vol. 66; no. 4; p. 386
Main Authors Eijsten, A, Knönagel, H, Hotz, E, Brütsch, H P, Hauri, D
Format Journal Article
LanguageEnglish
Published England 01.10.1990
Subjects
Administration, Intravesical
Adult
Aged
Aged, 80 and over
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Cystectomy
Drug Administration Schedule
Female
Humans
Male
Middle Aged
Mitomycin
Mitomycins - administration & dosage
Mitomycins - adverse effects
Mitomycins - therapeutic use
Time Factors
Urinary Bladder - drug effects
Urinary Bladder - pathology
Urinary Bladder Neoplasms - pathology
Urinary Bladder Neoplasms - prevention & control
Online AccessGet more information

Cover

More Information
Summary:After complete resection of superficial bladder carcinoma (Tis-2, G1-3), 75 patients were treated prophylactically with either 20 or 30 mg mitomycin C. Six patients developed a substantial reduction in bladder capacity (less than 200 ml). In 2 patients radical cystectomy of an otherwise tumour-free fibrotic bladder was necessary. The results of long-term treatment (2 years) suggest that reduced bladder capacity correlates with the cumulative dosage of mitomycin C.
ISSN:0007-1331
DOI:10.1111/j.1464-410X.1990.tb14959.x